The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?
Pfizer/Biohaven Is Only $10bn-Plus M&A In First Half
INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. In Vivo's sister publication Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
You may also be interested in...
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
Obeticholic acid failed to separate from placebo in a Phase III study of non-alcoholic steatohepatitis patients with cirrhosis, but Intercept said it still plans to refile an NDA for pre-cirrhotic NASH by year’s end.
Axcella’s AXA1125, a therapeutic combination of amino acids, shows liver stiffness, liver enzyme and fat reduction benefits in Phase IIb interim look, but the firm lacks the cash to complete the trial.